The Associated Press on MSN4d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...
GlobalData on MSN1d
Teva’s long-lasting schizophrenia injectable shines in Phase III
Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...
Bristol Myers presents new long-term data from EMERGENT study of COBENFY
Squibb “announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the ...
ABC News5d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug ... showed the likelihood of continuing treatment. After six months, 36 said they would continue taking Cobenfy after the trial if given the option ...